Antibiotic resistance fund aims 2-4 new antibiotics by 2030, page-11

PBT2 as antibiotics is still on the research stage, more likely brewing in their partner labs. Prior to discussion with FDA, they only need to broadcast good results when they think it necessary. In other words, if the data are not satisfactory, this project could be silently overlaid by new projects without further updates. Currently it is just one of their research interests. You know they used to spend millions of dollars in research even when there was no clinical trials. What they need to do was just briefly telling us they were expanding the compound collection and looking for more promising candidates in annual and semiannual reports.